The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Recombinant Peptide-Global Market Insights and Sales Trends 2024
Synopsis
A recombinant peptide therapy is produced through recombinant DNA technology. This involves inserting the DNA encoding the peptide into bacterial or mammalian cells, expressing the peptide in these cells and then purifying it from them.
The global Recombinant Peptide market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Recombinant Peptide in various end use industries. The expanding demands from the Oncology, Blood Disorders, Infectious Diseases and Autoimmune Diseases, are propelling Recombinant Peptide market. Glucagon, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Calcitonin segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Recombinant Peptide market, driven by demand from China, the second largest economy with some signs of stabilising, the Recombinant Peptide market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Recombinant Peptide, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Recombinant Peptide market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Recombinant Peptide market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Recombinant Peptide sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Recombinant Peptide covered in this report include Sandoz Pharma, Stada Arzneimittel, Amgen, Hospira, Actavis, Cipla Ltd., Wockhardt Ltd. and Biocon Ltd., etc.
The global Recombinant Peptide market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Sandoz Pharma
Stada Arzneimittel
Amgen
Hospira
Actavis
Cipla Ltd.
Wockhardt Ltd.
Biocon Ltd.
Global Recombinant Peptide market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Recombinant Peptide market, Segment by Type:
Glucagon
Calcitonin
Other
Global Recombinant Peptide market, by Application
Oncology
Blood Disorders
Infectious Diseases
Autoimmune Diseases
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Recombinant Peptide manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Recombinant Peptide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
A recombinant peptide therapy is produced through recombinant DNA technology. This involves inserting the DNA encoding the peptide into bacterial or mammalian cells, expressing the peptide in these cells and then purifying it from them.
The global Recombinant Peptide market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Recombinant Peptide in various end use industries. The expanding demands from the Oncology, Blood Disorders, Infectious Diseases and Autoimmune Diseases, are propelling Recombinant Peptide market. Glucagon, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Calcitonin segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Recombinant Peptide market, driven by demand from China, the second largest economy with some signs of stabilising, the Recombinant Peptide market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Recombinant Peptide, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Recombinant Peptide market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Recombinant Peptide market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Recombinant Peptide sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Recombinant Peptide covered in this report include Sandoz Pharma, Stada Arzneimittel, Amgen, Hospira, Actavis, Cipla Ltd., Wockhardt Ltd. and Biocon Ltd., etc.
The global Recombinant Peptide market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Sandoz Pharma
Stada Arzneimittel
Amgen
Hospira
Actavis
Cipla Ltd.
Wockhardt Ltd.
Biocon Ltd.
Global Recombinant Peptide market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Recombinant Peptide market, Segment by Type:
Glucagon
Calcitonin
Other
Global Recombinant Peptide market, by Application
Oncology
Blood Disorders
Infectious Diseases
Autoimmune Diseases
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Recombinant Peptide manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Recombinant Peptide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Recombinant Peptide Market Overview
1.1 Recombinant Peptide Product Overview
1.2 Recombinant Peptide Market Segment by Type
1.2.1 Glucagon
1.2.2 Calcitonin
1.2.3 Other
1.3 Global Recombinant Peptide Market Size by Type
1.3.1 Global Recombinant Peptide Market Size Overview by Type (2018-2029)
1.3.2 Global Recombinant Peptide Historic Market Size Review by Type (2018-2023)
1.3.3 Global Recombinant Peptide Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Recombinant Peptide Sales Breakdown by Type (2018-2023)
1.4.2 Europe Recombinant Peptide Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Recombinant Peptide Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Recombinant Peptide Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Recombinant Peptide Sales Breakdown by Type (2018-2023)
2 Global Recombinant Peptide Market Competition by Company
2.1 Global Top Players by Recombinant Peptide Sales (2018-2023)
2.2 Global Top Players by Recombinant Peptide Revenue (2018-2023)
2.3 Global Top Players by Recombinant Peptide Price (2018-2023)
2.4 Global Top Manufacturers Recombinant Peptide Manufacturing Base Distribution, Sales Area, Product Type
2.5 Recombinant Peptide Market Competitive Situation and Trends
2.5.1 Recombinant Peptide Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Recombinant Peptide Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Recombinant Peptide as of 2022)
2.7 Date of Key Manufacturers Enter into Recombinant Peptide Market
2.8 Key Manufacturers Recombinant Peptide Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Recombinant Peptide Status and Outlook by Region
3.1 Global Recombinant Peptide Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Recombinant Peptide Historic Market Size by Region
3.2.1 Global Recombinant Peptide Sales in Volume by Region (2018-2023)
3.2.2 Global Recombinant Peptide Sales in Value by Region (2018-2023)
3.2.3 Global Recombinant Peptide Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Recombinant Peptide Forecasted Market Size by Region
3.3.1 Global Recombinant Peptide Sales in Volume by Region (2024-2029)
3.3.2 Global Recombinant Peptide Sales in Value by Region (2024-2029)
3.3.3 Global Recombinant Peptide Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Recombinant Peptide by Application
4.1 Recombinant Peptide Market Segment by Application
4.1.1 Oncology
4.1.2 Blood Disorders
4.1.3 Infectious Diseases
4.1.4 Autoimmune Diseases
4.1.5 Other
4.2 Global Recombinant Peptide Market Size by Application
4.2.1 Global Recombinant Peptide Market Size Overview by Application (2018-2029)
4.2.2 Global Recombinant Peptide Historic Market Size Review by Application (2018-2023)
4.2.3 Global Recombinant Peptide Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Recombinant Peptide Sales Breakdown by Application (2018-2023)
4.3.2 Europe Recombinant Peptide Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Recombinant Peptide Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Recombinant Peptide Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Recombinant Peptide Sales Breakdown by Application (2018-2023)
5 North America Recombinant Peptide by Country
5.1 North America Recombinant Peptide Historic Market Size by Country
5.1.1 North America Recombinant Peptide Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Recombinant Peptide Sales in Volume by Country (2018-2023)
5.1.3 North America Recombinant Peptide Sales in Value by Country (2018-2023)
5.2 North America Recombinant Peptide Forecasted Market Size by Country
5.2.1 North America Recombinant Peptide Sales in Volume by Country (2024-2029)
5.2.2 North America Recombinant Peptide Sales in Value by Country (2024-2029)
6 Europe Recombinant Peptide by Country
6.1 Europe Recombinant Peptide Historic Market Size by Country
6.1.1 Europe Recombinant Peptide Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Recombinant Peptide Sales in Volume by Country (2018-2023)
6.1.3 Europe Recombinant Peptide Sales in Value by Country (2018-2023)
6.2 Europe Recombinant Peptide Forecasted Market Size by Country
6.2.1 Europe Recombinant Peptide Sales in Volume by Country (2024-2029)
6.2.2 Europe Recombinant Peptide Sales in Value by Country (2024-2029)
7 Asia-Pacific Recombinant Peptide by Region
7.1 Asia-Pacific Recombinant Peptide Historic Market Size by Region
7.1.1 Asia-Pacific Recombinant Peptide Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Recombinant Peptide Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Recombinant Peptide Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Recombinant Peptide Forecasted Market Size by Region
7.2.1 Asia-Pacific Recombinant Peptide Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Recombinant Peptide Sales in Value by Region (2024-2029)
8 Latin America Recombinant Peptide by Country
8.1 Latin America Recombinant Peptide Historic Market Size by Country
8.1.1 Latin America Recombinant Peptide Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Recombinant Peptide Sales in Volume by Country (2018-2023)
8.1.3 Latin America Recombinant Peptide Sales in Value by Country (2018-2023)
8.2 Latin America Recombinant Peptide Forecasted Market Size by Country
8.2.1 Latin America Recombinant Peptide Sales in Volume by Country (2024-2029)
8.2.2 Latin America Recombinant Peptide Sales in Value by Country (2024-2029)
9 Middle East and Africa Recombinant Peptide by Country
9.1 Middle East and Africa Recombinant Peptide Historic Market Size by Country
9.1.1 Middle East and Africa Recombinant Peptide Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Recombinant Peptide Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Recombinant Peptide Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Recombinant Peptide Forecasted Market Size by Country
9.2.1 Middle East and Africa Recombinant Peptide Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Recombinant Peptide Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Sandoz Pharma
10.1.1 Sandoz Pharma Company Information
10.1.2 Sandoz Pharma Introduction and Business Overview
10.1.3 Sandoz Pharma Recombinant Peptide Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Sandoz Pharma Recombinant Peptide Products Offered
10.1.5 Sandoz Pharma Recent Development
10.2 Stada Arzneimittel
10.2.1 Stada Arzneimittel Company Information
10.2.2 Stada Arzneimittel Introduction and Business Overview
10.2.3 Stada Arzneimittel Recombinant Peptide Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Stada Arzneimittel Recombinant Peptide Products Offered
10.2.5 Stada Arzneimittel Recent Development
10.3 Amgen
10.3.1 Amgen Company Information
10.3.2 Amgen Introduction and Business Overview
10.3.3 Amgen Recombinant Peptide Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Amgen Recombinant Peptide Products Offered
10.3.5 Amgen Recent Development
10.4 Hospira
10.4.1 Hospira Company Information
10.4.2 Hospira Introduction and Business Overview
10.4.3 Hospira Recombinant Peptide Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Hospira Recombinant Peptide Products Offered
10.4.5 Hospira Recent Development
10.5 Actavis
10.5.1 Actavis Company Information
10.5.2 Actavis Introduction and Business Overview
10.5.3 Actavis Recombinant Peptide Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Actavis Recombinant Peptide Products Offered
10.5.5 Actavis Recent Development
10.6 Cipla Ltd.
10.6.1 Cipla Ltd. Company Information
10.6.2 Cipla Ltd. Introduction and Business Overview
10.6.3 Cipla Ltd. Recombinant Peptide Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Cipla Ltd. Recombinant Peptide Products Offered
10.6.5 Cipla Ltd. Recent Development
10.7 Wockhardt Ltd.
10.7.1 Wockhardt Ltd. Company Information
10.7.2 Wockhardt Ltd. Introduction and Business Overview
10.7.3 Wockhardt Ltd. Recombinant Peptide Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Wockhardt Ltd. Recombinant Peptide Products Offered
10.7.5 Wockhardt Ltd. Recent Development
10.8 Biocon Ltd.
10.8.1 Biocon Ltd. Company Information
10.8.2 Biocon Ltd. Introduction and Business Overview
10.8.3 Biocon Ltd. Recombinant Peptide Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Biocon Ltd. Recombinant Peptide Products Offered
10.8.5 Biocon Ltd. Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Recombinant Peptide Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Recombinant Peptide Industrial Chain Analysis
11.4 Recombinant Peptide Market Dynamics
11.4.1 Recombinant Peptide Industry Trends
11.4.2 Recombinant Peptide Market Drivers
11.4.3 Recombinant Peptide Market Challenges
11.4.4 Recombinant Peptide Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Recombinant Peptide Distributors
12.3 Recombinant Peptide Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
